News

03.16.21

Press Release

Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference

Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products SEATTLE, Wash. and VANCOUVER, British Columbia, March 16, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich,…

/Read More

03.15.21

Press Release

Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors

SEATTLE, Wash. and VANCOUVER, British Columbia, March 15, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company’s Board of Directors,…

/Read More

03.11.21

Press Release

Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update

SEATTLE, Wash and VANCOUVER, British Columbia, March 11, 2021  — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent…

/Read More

03.04.21

Press Release

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on March 11, 2021

SEATTLE, Wash. and VANCOUVER, British Columbia / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its fourth quarter and year-end 2020 financial results and provide an update on the cytisinicline development program on Thursday,…

/Read More

02.24.21

Press Release

Achieve Life Sciences Announces Presentation of Data on Smoker and E-Cigarette User Attitudes and Perceptions on Quitting at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting

SEATTLE, Wash. and VANCOUVER, British Columbia, February 24, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT…

/Read More